Strong demand continues as buybacks resume
- Net new business awards rose 28.2% from last year to $795.7 million in Q2 2026.
- The company resumed share repurchases by buying back $294.7 million of stock in Q2.
- Trial bookings are shifting back to historical norms with oncology driving over half of new awards.
- Backlog remains large, giving Medpace a strong base of future work to convert into revenue.
- The main debate is whether strong bookings can keep beating biotech funding cycles and margin risks.
Demand is answering the key question
Medpace is showing clear demand for its focused clinical trial model. Net new business awards were $795.7 million in Q2 2026, up 28.2% from last year. This resulted in a strong 1.13x net book-to-bill ratio. That matters because new awards are the best early sign of future sales for a contract research organization, or CRO.
The bull case is simple. Small and mid-sized drug developers still need help running trials, and Medpace offers a full-service model across Phase I through Phase IV. Its backlog gives it work to convert into revenue, and Q2 showed that customers are still signing new work at a healthy pace. Crucially, the company resumed share repurchases, buying back 706,000 shares for $294.7 million, resolving a major open question from earlier in the year.
The bear case is not about whether Medpace is a good operator. It is about cycle risk, margins, and price. Biotech clients can cut trial spending when funding gets tight. A high backlog burn rate of 24.1% in Q2 means the company must keep winning large volumes of new work to grow. Additionally, a significant portion of revenue growth continues to come from lower-margin reimbursed out-of-pocket expenses.
Paid to run the trial machine
Medpace helps drug, biotech, and medical device companies run clinical trials. It designs development plans, manages projects, handles regulatory work, monitors clinical sites, manages data, watches drug safety, and supports lab, imaging, and heart reading services.
Most contracts are fee-for-service. They are usually priced as fixed-fee work or by units of service. That means Medpace can make good money when it estimates trial costs well and keeps teams busy. It can also get hurt when a fixed-fee contract takes more work than planned.
Two numbers drive the model. Net new business awards show fresh signed work after cancellations. Backlog shows contracted work not yet recognized as revenue. The risk is that backlog is not cash in the bank. Customers can delay, cut, or cancel trials, often for reasons outside the control of the company.
Where the trial work sits
Full-service clinical development
This is the core product. Medpace supports trials from Phase I through Phase IV, which lets clients use one main partner instead of many vendors.
Oncology trials
Cancer trials remain one of Medpace's key strengths. In Q2 2026, oncology represented over half of overall bookings.
Metabolic Disease trials
Metabolic was a major driver of recent growth, but awards have moderated as the mix shifts back to historical averages.
Central Nervous System trials
CNS work covers brain and nerve disorders. It remains a key focus area for clinical research.
Cardiology trials
Heart disease work is a long-running clinical research need. It provides a stable base of trial work.
AVAI trials
AVAI means antiviral and anti-infective work. It is smaller than metabolic and oncology, but still part of the broad trial platform.
One segment, several therapeutic areas
Medpace reports one operating segment. The mix below uses recent revenue trends by therapeutic area, with oncology leading the current bookings growth.
What could break the story
Biotech funding turns down
High impact · Medium oddsMedpace depends heavily on small and mid-sized biopharma clients. If funding dries up, these clients may delay, shrink, or cancel trials.
Backlog does not convert
High impact · Medium oddsBacklog is not guaranteed revenue, and the current burn rate is high at 24.1 percent. Many clinical trial contracts can be changed or canceled. If conversion slows, revenue growth can fall.
Margin mix gets worse
Medium impact · Medium oddsReimbursed out-of-pocket expenses are a large part of growth. These pass-through costs can make revenue look bigger while adding less profit than service revenue. If service margins weaken, the growth headline may hide pressure underneath.
AI and tech gap
Medium impact · Medium oddsThe company added a risk about machine learning and generative AI in 2025. Poor controls could hurt quality, but too little investment could leave Medpace behind rivals using better trial tools.
In one breath
What does Medpace do?
Medpace is a contract research organization. It helps drug, biotech, and medical device companies run clinical trials, from early human studies through post-market work.
How does Medpace make money?
Medpace charges clients for clinical development services. Contracts are often fixed-fee or based on units of service, and revenue is recognized as trial work is performed.
Why do investors watch net new business awards?
Net new business awards show new trial work won after cancellations. For Medpace, they are a key early signal of future revenue because awards can later move into backlog and then sales.
Why was the Q2 buyback resumption important?
Medpace paused its share repurchases in Q1, raising concerns about capital returns. By buying back $294.7 million in stock during Q2, management signaled confidence and provided support for earnings per share.
